As GPX4 inhibitor having appropriate pharmacokinetic properties for in vivo study are currently in development2, further studies employing GPX4 inhibitor in orthotopic tumor models with TGF-β1-rich microenvironments may support our hypothesis. This evidence concerns the gene TGFB1 and neoplasm.